A woman who developed breast cancer after taking combination hormone therapy drugs including Premarin, Provera and Prempro for 15 years won a $5 million award against drug companies Wyeth and Upjohn this month.
Product liability plaintiffs should have been permitted to introduce expert testimony linking the short-term use of Prempro to a risk of breast cancer, the 8th Circuit has ruled in reversing a summary judgment.
Published: June 7, 2012
Tags: Accutane, adverse events, Avandia, Bayer, Chantix, Coumadin, drug litigation, FDA, Food and Drug Administration, GlaxoSmithKline, Hoffman-LaRoche, Institute for Safe Medication Practices, Johnson & Johnson, Levaquin, Pfizer, Pradaxa, prescription drugs, Reglan, Wyeth, Yasmin, Yaz
The anti-nausea drug Reglan and its generic counterparts were the drugs most frequently cited in litigation in 2011, according to a consumer watchdog’s latest analysis of Food and Drug Administration statistics.
A 65-year-old elementary school principal has won a $4 million verdict in Connecticut federal court against the maker of the menopause drug Prempro for causing her breast cancer.
A product liability plaintiff could not show that the alleged failure of pharmaceutical companies to warn about the dangers of their hormone therapy drugs was the proximate cause of her breast cancer, a U.S. District Court in South Carolina has ruled in granting summary judgment.
A product liability lawsuit against drug maker Wyeth was not barred by the plaintiff’s failure to declare her claim as an asset in her bankruptcy case prior to obtaining a discharge of debts, a U.S. District Court in Mississippi has ruled in denying summary judgment.
A $28 million award of punitive damages was not unconstitutionally excessive in a product liability case brought by a woman who contracted breast cancer after taking hormone replacement therapy drugs, a Pennsylvania appellate court has ruled in reversing judgment.
Evidence of Wyeth’s marketing campaign for “off-label” Prempro uses was admissible in a product liability case brought by a woman who contracted breast cancer after taking the drug, a Pennsylvania appellate court has ruled.
An antitrust lawsuit filed in federal court in Mississippi alleges that Wyeth Pharmaceuticals used fraudulently obtained patents as part of a scheme to delay the introduction of generic versions of the anti-depressant Effexor XR.
A jury’s $1.6 million verdict for the plaintiff in a Prempro case should be reinstated along with a sealed punitive award against drugmaker Wyeth, a Pennsylvania appellate court has ruled.